STOCK TITAN
  1. Home
  2. News
  3. GERN

Geron Corp - GERN STOCK NEWS

Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.

Geron Corporation (GERN) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class therapies for cancer. The company's cornerstone product candidate is Imetelstat, a novel telomerase inhibitor currently in clinical development. Telomerase is an enzyme that allows cancer cells to maintain telomere length, essential for limitless cellular replication.

Imetelstat is a potent, specific inhibitor of telomerase and holds promise for treating various hematologic myeloid malignancies. Based on clinical data obtained in late 2012, Geron is exploring the potential of Imetelstat to treat conditions such as myelofibrosis (MF), myelodysplastic syndromes (MDS), and acute myelogenous leukemia (AML).

Geron earns revenue through a mix of collaboration agreements, milestones, royalties, and licensing arrangements. The company is the exclusive developer of Imetelstat and possesses various rights to the drug. Operating as a single segment focused on oncology, Geron is committed to advancing its research to bring effective cancer treatments to market.

Stay updated with the latest news and developments from Geron Corporation to learn more about their groundbreaking research and progress in cancer treatment.

News

Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

Rhea-AI Summary
Geron Corporation's Marketing Authorization Application (MAA) for imetelstat has been validated by the European Medicines Agency (EMA), bringing them closer to potentially offering the treatment to lower risk MDS patients in the EU. Clinical results have shown significant efficacy, with higher transfusion independence rates and increased hemoglobin levels in imetelstat-treated patients compared to placebo. The MAA is now under regulatory review and expected to take approximately 14 months. The company is also awaiting a decision from the U.S. FDA with a PDUFA action date of June 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none
-
News

Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer

Rhea-AI Summary
Geron Corporation appoints Michelle Robertson as CFO and Treasurer, effective September 25, 2023. Olivia Bloom retires after 30 years with the company. Robertson brings over 30 years of financial experience. Inducement grants of 1.6 million shares of Geron common stock planned for Robertson.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
management
-
News

Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting

Rhea-AI Summary
Geron announces positive data from IMerge Phase 3 trial for imetelstat in lower risk MDS, with significant increases in transfusion independence and hemoglobin levels, improvement in fatigue, and manageable safety profile. New Drug Application for imetelstat accepted for review by FDA with PDUFA action date of June 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition clinical trial
News

Geron to Participate in the Baird 2023 Global Healthcare Conference

Rhea-AI Summary
Geron CEO to participate in fireside chat at Baird 2023 Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences
-
News

Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

Rhea-AI Summary
Geron Corporation announced FDA review and PDUFA action date of June 16, 2024 for imetelstat NDA. Expecting US launch by H1 2024, subject to FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.31%
Tags
none
-
News

Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS

Rhea-AI Summary
Geron's NDA for imetelstat accepted by FDA for the treatment of anemia in MDS patients. Positive efficacy results and significant increase in hemoglobin levels. Expectation of changing standard of care in lower risk MDS. Safety consistent with prior clinical experience. FDA has up to 74 days to notify PDUFA action date. MAA submission in EU expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
clinical trial
News

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Geron Corporation has granted non-statutory stock options to newly hired employees, totaling 189,850 shares. The options were granted at an exercise price of $2.70 per share and have a 10-year term. Some options vest over four years, while others vest upon achievement of a regulatory milestone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
-
News

Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
earnings
-
News

Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
earnings
News

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none

FAQ

What is the current stock price of Geron (GERN)?

The current stock price of Geron (GERN) is $4.07 as of November 22, 2024.

What is the market cap of Geron (GERN)?

The market cap of Geron (GERN) is approximately 2.5B.

What is the primary focus of Geron Corporation?

Geron Corporation is focused on developing first-in-class cancer therapies, particularly a telomerase inhibitor named Imetelstat.

What is Imetelstat?

Imetelstat is a novel, first-in-class telomerase inhibitor developed by Geron Corporation for treating various hematologic myeloid malignancies.

Which conditions is Imetelstat being developed to treat?

Imetelstat is being developed to treat myelofibrosis (MF), myelodysplastic syndromes (MDS), and acute myelogenous leukemia (AML).

How does Imetelstat work?

Imetelstat works by inhibiting telomerase, an enzyme that enables cancer cells to maintain telomere length and replicate indefinitely.

What revenue streams does Geron Corporation rely on?

Geron earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements.

Is Geron Corporation a diversified company?

No, Geron operates as a single segment focused on the development of therapeutic products for oncology.

What is the significance of telomerase in cancer treatment?

Telomerase allows cancer cells to maintain telomere length, which is crucial for their endless replication. Inhibiting telomerase can potentially limit cancer growth.

Has Geron Corporation achieved any significant milestones?

Yes, Geron has obtained promising clinical data for Imetelstat and continues to develop it for various cancer treatments.

Where can I find the latest news about Geron Corporation?

You can find the latest news and developments about Geron Corporation on their official website and dedicated stock market websites like StockTitan.

What makes Imetelstat unique among cancer therapies?

Imetelstat is unique because it is a first-in-class telomerase inhibitor, targeting a critical enzyme that allows cancer cells to replicate indefinitely.

Stock GERN logo
Geron Corp

Nasdaq:GERN

GERN Rankings

#1845 Ranked by Market Cap
N/A Ranked by Dividends

GERN Stock Data

2.48B
603.98M
0.09%
85.33%
12.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FOSTER CITY